Trial Profile
A Phase II expansion trial to further explore NGM282's broad activity in biopsy-confirmed Nonalcoholic Steatohepatits (NASH).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Feb 2020
Price :
$35
*
At a glance
- Drugs Aldafermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 30 Oct 2017 New trial record